“Incremental Risk of Adverse Events with Oral Janus Kinase Inhibitor Use in Atopic Dermatitis and Other Indications: A Systematic Review and Meta-Analysis” (2024) SKIN The Journal of Cutaneous Medicine, 8(1), p. s320. doi:10.25251/skin.8.supp.320.